



# New Hampshire Medicaid Fee-for-Service Program

## Prior Authorization Drug Approval Form

Carisoprodol and Combination Medications

DATE OF MEDICATION REQUEST:     /     /

### SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

GENDER: ☐ Male ☐ Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

### SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FAX NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

### SECTION III: CLINICAL HISTORY

- For what condition is this medication being prescribed?  
\_\_\_\_\_
- Has the patient had a defined failure of, contraindication to, or intolerance to a trial of at least one preferred analgesic? ☐ Yes ☐ No
  - If yes, please list treatment failures and provide dates:  
\_\_\_\_\_  
\_\_\_\_\_
- Has the patient had a defined failure of, contraindication to, or intolerance to a trial of at least two preferred skeletal muscle relaxants? ☐ Yes ☐ No
  - If yes, please list treatment failures and provide dates:  
\_\_\_\_\_  
\_\_\_\_\_

(Form continued on next page.)

Phone: 1-866-675-7755

Fax: 1-888-603-7696

© 2021–2025 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 06/05/2025





**New Hampshire Medicaid Fee-for-Service Program  
Prior Authorization Drug Approval Form**

Carisoprodol and Combination Medications

DATE OF MEDICATION REQUEST:     /     /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (*Continued*)**

4. Is the prescribed duration of treatment for short-term therapy (up to three consecutive weeks at a time)? ☐ Yes ☐ No
5. Does the patient have an active substance use disorder? ☐ Yes ☐ No
6. Does the patient have a history of gastrointestinal (GI) bleeding (for aspirin-containing products only)? ☐ Yes ☐ No

Provide any additional information that would help in the decision-making process. *If additional space is needed, please use another page.*

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: \_\_\_\_\_ DATE: \_\_\_\_\_

Phone: 1-866-675-7755

Fax: 1-888-603-7696

